Stockreport

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder [Yahoo! Finance]

Cybin Inc. Common Shares  (CYBN) 
PDF - Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale (" MADRS ") score compared to baseline at 12 months after two 16 mg d [Read more]